X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Aventis Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs MYLAN (US) - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SANOFI INDIA   MYLAN
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
MYLAN
Dec-14
SANOFI INDIA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4,9454,238-   
Low Rs3,9012,986-   
Sales per share (Unadj.) Rs1,081.81,450.7-  
Earnings per share (Unadj.) Rs141.6174.8-  
Cash flow per share (Unadj.) Rs185.9281.3-  
Dividends per share (Unadj.) Rs33.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs868.8721.1-  
Shares outstanding (eoy) m23.03378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x4.12.5 164.2%   
Avg P/E ratio x31.220.7 151.2%  
P/CF ratio (eoy) x23.812.8 185.3%  
Price / Book Value ratio x5.15.0 101.6%  
Dividend payout %23.30-   
Avg Mkt Cap Rs m101,8621,366,627 7.5%   
No. of employees `0003.225.0 13.0%   
Total wages/salary Rs m3,6850-   
Avg. sales/employee Rs Th7,691.921,955.7 35.0%   
Avg. wages/employee Rs Th1,137.70-   
Avg. net profit/employee Rs Th1,006.52,644.9 38.1%   
INCOME DATA
Net Sales Rs m24,914548,892 4.5%  
Other income Rs m807-3,200 -25.2%   
Total revenues Rs m25,721545,693 4.7%   
Gross profit Rs m5,372136,512 3.9%  
Depreciation Rs m1,02240,314 2.5%   
Interest Rs m1123,676 0.0%   
Profit before tax Rs m5,14669,323 7.4%   
Minority Interest Rs m0-284 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8862,915 64.7%   
Profit after tax Rs m3,26066,123 4.9%  
Gross profit margin %21.624.9 86.7%  
Effective tax rate %36.64.2 871.6%   
Net profit margin %13.112.0 108.6%  
BALANCE SHEET DATA
Current assets Rs m14,432482,549 3.0%   
Current liabilities Rs m6,010377,257 1.6%   
Net working cap to sales %33.819.2 176.2%  
Current ratio x2.41.3 187.7%  
Inventory Days Days6178 78.0%  
Debtors Days Days28107 26.5%  
Net fixed assets Rs m7,991126,985 6.3%   
Share capital Rs m23019,410 1.2%   
"Free" reserves Rs m19,7780-   
Net worth Rs m20,008272,853 7.3%   
Long term debt Rs m0407,616 0.0%   
Total assets Rs m27,7701,099,028 2.5%  
Interest coverage x468.83.9 11,935.5%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.90.5 179.6%   
Return on assets %11.88.2 144.2%  
Return on equity %16.324.2 67.2%  
Return on capital %25.813.6 189.2%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m1,0490-   
CASH FLOW
From Operations Rs m4,35172,152 6.0%  
From Investments Rs m-787-56,901 1.4%  
From Financial Activity Rs m-1,884-19,012 9.9%  
Net Cashflow Rs m1,680-3,761 -44.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.1 Rs / USD

Compare SANOFI INDIA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SANOFI INDIA With: ALEMBIC LTD  TTK HEALTHCARE  STRIDES PHARMA SCIENCE  WYETH LTD  CADILA HEALTHCARE  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views On News

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 22, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - FRESENIUS KABI ONCO. COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS